Author

Soon Myung Kang

NA Vaccine Institute (South Korea)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Arnaud Debin· 1 shared Dong-Ho KimiD· 1 shared Éric PérouzeliD· 1 shared M.-G. L. Lee· 1 shared Seung‐Beom HongiD· 1 shared Seung‐Hwan LeeiD· 1 shared Young-Ho Choi· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Arnaud Debin

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ImmunologyCancersPeer-reviewedDec 8, 2023

The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.

Seung‐Hwan Lee, Young-Ho Choi, Soon Myung Kang…·Dong-Ho Kim

This paper evaluates Nexavant, a TLR3 agonist, showing enhanced anti-cancer effects and synergy with anti-PD-1 therapy through immune cell infiltration.

10 citations

mouseexperimental assay

𝕏 PostBluesky